FDA Approves Avastin for the Most Common Type of Kidney Cancer
The US FDA has approved Genentech's Avastin (bevacizumab) plus interferon-alfa for people with metastatic renal cell carcinoma, the most common type of kidney cancer.
The US Food and Drug Administration has approved Genentech's Avastin (bevacizumab) plus interferon-alfa for people with metastatic renal cell carcinoma, the most common type of kidney cancer.
This FDA approval is based on data from a Phase 3 study of patients with previously untreated metastatic renal cell carcinoma. The study showed patients who received Avastin plus interferon-alfa lived 10.2 months without disease progression compared with 5.4 months for those who received interferon-alfa alone.
Avastin is a biologic antibody designed to specifically bind to vascular endothelial growth factor (VEGF) that plays an important role throughout the lifecycle of a tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the blood supply to a tumor by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. Avastin does not bind to receptors on normal or cancer cells.
Avastin was the first anti-angiogenesis therapy approved by the FDA. Avastin is also indicated for the first- or second-line treatment of metastatic colorectal cancer plus intravenous 5-FU based chemotherapy and for the first-line treatment of unresectable, locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
